154 related articles for article (PubMed ID: 16981834)
1. Novel targets in prostate cancer.
Berthold DR; Moore MJ
Expert Opin Ther Targets; 2006 Oct; 10(5):777-80. PubMed ID: 16981834
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for prostate cancer.
Asatiani E; Gelmann EP
Expert Opin Ther Targets; 2005 Apr; 9(2):283-98. PubMed ID: 15934916
[TBL] [Abstract][Full Text] [Related]
3. Horizon scanning for novel therapeutics for the treatment of prostate cancer.
Bianchini D; Zivi A; Sandhu S; de Bono JS
Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208
[TBL] [Abstract][Full Text] [Related]
4. Cell mates: paracrine and stromal targets for prostate cancer therapy.
Sluka P; Davis ID
Nat Rev Urol; 2013 Aug; 10(8):441-51. PubMed ID: 23857181
[TBL] [Abstract][Full Text] [Related]
5. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.
Levy O; Brennen WN; Han E; Rosen DM; Musabeyezu J; Safaee H; Ranganath S; Ngai J; Heinelt M; Milton Y; Wang H; Bhagchandani SH; Joshi N; Bhowmick N; Denmeade SR; Isaacs JT; Karp JM
Biomaterials; 2016 Jun; 91():140-150. PubMed ID: 27019026
[TBL] [Abstract][Full Text] [Related]
6. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
[TBL] [Abstract][Full Text] [Related]
7. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
8. Agents targeting prostate cancer bone metastasis.
Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle therapeutics for prostate cancer treatment.
Sanna V; Sechi M
Nanomedicine; 2012 Sep; 8 Suppl 1():S31-6. PubMed ID: 22640911
[TBL] [Abstract][Full Text] [Related]
10. Targeting prostate cancer stem cells.
Crea F; Mathews LA; Farrar WL; Hurt EM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1105-13. PubMed ID: 19925394
[TBL] [Abstract][Full Text] [Related]
11. Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A; Summerlee AJ; Silvertown JD
Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
[TBL] [Abstract][Full Text] [Related]
12. MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y; Cozzi PJ
Curr Cancer Drug Targets; 2007 May; 7(3):259-71. PubMed ID: 17504123
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
14. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
15. Novel targets in pancreatic cancer: focus on future paths to therapy.
Cohen SJ; Burtness BA
Expert Opin Ther Targets; 2006 Oct; 10(5):771-5. PubMed ID: 16981833
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
18. Drug design strategies for the treatment of prostate cancer.
Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
[TBL] [Abstract][Full Text] [Related]
19. Current prospects and challenges of nanomedicine delivery in prostate cancer therapy.
Gupta S; Gupta PK; Dharanivasan G; Verma RS
Nanomedicine (Lond); 2017 Dec; 12(23):2675-2692. PubMed ID: 29098929
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
